Group 1 - The innovative drug sector has seen a significant recovery this year, becoming a popular investment area in the secondary market, with public funds reporting a peak in pharmaceutical-themed fund applications in the second quarter, totaling around 30 products, comparable to the total number for the entire year of 2024 [1][2] - Public funds heavily invested in innovative drug stocks have achieved returns exceeding 80% this year, leading to substantial inflows into related thematic index funds, such as the Huatai-PineBridge ETF, which saw net inflows of over 4.4 billion yuan, increasing its scale from 653 million yuan to 6.489 billion yuan [2] - The investment sentiment in the innovative drug sector is rising, with many institutional investors showing strong interest, and the approval speed for pharmaceutical-themed funds is accelerating to meet market demand [4][5] Group 2 - The innovative drug sector's valuation is under discussion, with some experts suggesting that while the current valuation is not low, it has not yet reached a bubble stage, indicating potential for further increases as more drug pipelines advance to late-stage clinical trials [4][5][6] - The investment opportunities in the innovative drug sector are seen as a result of ten years of research and development, with expectations for significant business development contributions and improved financial reports in the coming years [7] - Different fund companies are adopting varied strategies for product layout, with a focus on active management products in the innovative drug sector, which may offer better opportunities for excess returns compared to passive products [8]

Core Viewpoint - The A-share market has experienced a structural "market" in public fund issuance since June, with a significant increase in new fund sizes, particularly in bond funds, while passive index products have seen a decline in popularity [1][2]. Fund Issuance Overview - The total new fund issuance in June exceeded 90 billion yuan, with bond funds raising 43.285 billion yuan, accounting for 47.63% of the total, and an average size of 19.68 billion yuan per fund [3]. - Notably, two policy financial bond index funds raised 60.01 billion yuan and 60 billion yuan respectively, indicating strong institutional demand for high-quality pure bond products [3]. Fund Types and Performance - Mixed-asset FOF funds raised 91.11 billion yuan, representing 10.03% of the total, with the largest fund, Oriental Red Yingfeng, raising 65.73 billion yuan in just 7 days, highlighting the growing recognition of asset allocation products [4]. - The issuance of mixed funds reached 215.71 billion yuan, the highest proportion since January 2023, reflecting institutional enthusiasm for equity market positioning [4]. Passive Index Products - The issuance of passive index products has cooled, with many tracking broad indices like the CSI A500 and CSI 300, showing limited differentiation and lower fundraising amounts, such as 2.52 billion yuan and 2.34 billion yuan for specific ETFs [5]. Innovative Fund Trends - The popularity of new floating-rate funds has surged, with 13 out of 26 approved funds raising over 12.6 billion yuan, indicating a significant advancement in fund fee reform [6]. - Innovative funds, such as the first central enterprise commercial real estate REIT, raised 5 billion yuan and ended fundraising early, reflecting market interest in quality asset securitization products [6]. Market Dynamics - The new fund market continues to reflect a "strong bond, weak equity" trend, driven by decreased investor risk appetite and a shift towards low-volatility bond products [7]. - Despite overall market issuance differentiation, innovative products like Sci-Tech theme ETFs and REITs have attracted attention, indicating a demand for structural investment opportunities [7]. Future Outlook - As market conditions improve, the issuance of floating-rate funds is expected to continue, with a gradual recovery in equity fund issuance while bond funds will remain crucial in asset allocation [8].

Group 1 - The core point of the news is the announcement of the listing of the Bosera CSI A100 ETF, which will be listed on June 24, 2025, with a total trading share of 236 million [1] - As of June 17, 2025, the fund's asset allocation shows that bank deposits and settlement reserves account for 89.49% of total assets, while stock investments account for 10.51% [1] - In June, a total of 15 stock ETFs have announced their listings, with an average position of only 17.18%, indicating a generally low investment level among newly listed ETFs [1] Group 2 - The average fundraising for the newly announced ETFs in June is 364 million shares, with the largest being the Huaan Hang Seng Index Hong Kong Stock Connect ETF at 590 million shares [2] - Institutional investors hold an average of 16.72% of the shares in these ETFs, with the highest proportions in the Xingyin Shanghai Stock Exchange Science and Technology Innovation Board Comprehensive Price ETF at 59.97% [2] - The table provided lists various ETFs, their establishment dates, fundraising scales, and asset allocation percentages, highlighting the differences in investment strategies among these funds [2][3]

Core Viewpoint - The public fund issuance market continues to show a strong preference for bond funds, particularly certificates of deposit funds, while equity funds face challenges in fundraising [1][4]. Fund Issuance Overview - A total of 15 new funds were established last week, with a total issuance scale of 89.34 billion yuan, predominantly driven by bond funds, which raised 76.53 billion yuan, accounting for 85.66% of the total [1][4]. - The top fund, "People's Insurance Zhongzheng Interbank Certificate of Deposit AAA Index 7-Day Holding," raised 39.10 billion yuan with a subscription period of only 9 days, indicating high investor enthusiasm [2][3]. Fund Types and Trends - The issuance of equity products, including stock and mixed funds, was limited, with only 4 and 6 new funds respectively, raising 5.49 billion yuan and 6.06 billion yuan, which together accounted for less than 15% of the total [3][4]. - The market for passive index bond funds is expanding from interest rate bonds to credit bonds and niche sectors, with fund managers designing differentiated products to meet institutional needs [2][4]. Market Characteristics - The current fund issuance market exhibits three main characteristics: 1. Risk-averse sentiment is driving demand for low-risk products like interbank certificate of deposit funds and short-term bond funds [4]. 2. There is a divergence in the popularity of index investments, with broad-based ETFs facing challenges while thematic products require more time to cultivate the market [4]. 3. The issuance of equity products has entered a "frozen period," leading institutions to consider long-term investment strategies such as regular investment plans [4].

证券研究报告 | 金融工程 2025 年 05 月 24 日 刚需+出海+历史低位，多重因素凸显制药价值 ——华宝中证制药 ETF 投资价值分析 随着保健意识的提升及国内人口老龄化趋势的发展，药品作为人们生活中的刚 性需求，其市场需求量日益增长。从供给端来看，原研药专利集中到期，创新 药频获出海订单，中药受政策大力扶持，各细分领域药企均迎来发展机遇。时 逢相关标的位于历史的价格低位，药品制造业显示出一定的投资机会。华宝中 证制药 ETF（认购代码：562053.OF）通过紧密跟踪中证制药指数，一键式配 置制药行业优质上市企业，值得投资者关注。 任瞳 S1090519080004 rentong@cmschina.com.cn ❑ 风险提示：本报告仅作为投资参考，基金产品过往业绩并不预示其未来表 现，亦不构成投资收益的保证或投资建议，新发基金无历史业绩可参考。 敬请阅读末页的重要说明 专题报告 ❑ 在新兴市场经济快速发展和各国医疗保障制度的逐渐完整之下，全球医药 市场规模仍旧维持着稳定增长态势。而据统计，我国的人均药品用量仍远 低于世界发达国家水平，国内药品用量的需求增长仍然具有较大的空间。 ❑ 在供给端，各细 ...